CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Current assets:
Cash and cash equivalents	$ 7,786,743
Accounts receivable, net of allowance of $11,968 and $4,500 at September 30, 2020 and 2019, respectively	194,319	$ 839,951
Inventories	497,367	142,629
Prepaid expenses and other current assets	599,296	604,740
Total current assets	9,077,725	2,146,308
Property and equipment, net	1,277,655	226,221
Other assets:
Deferred offering costs		109,698
Deposits	95,083	62,351
Goodwill	285,386	285,386
Intangible assets, net	605,330	734,771
Total Assets	11,341,179	3,564,735
Current liabilities:
Accounts payable and accrued liabilities	1,926,427	1,616,997
Promissory notes payable-current portion	329,299
Secured convertible notes payable , net of debt issuance costs	1,499,116
Deferred revenue	511,036	628,993
Total current liabilities	4,265,878	2,245,990
Long term accrued liabilities	848,307	621,970
Promissory notes payable-long term portion	517,488
Secured convertible notes payable, net of debt issuance costs		1,442,497
Secured convertible notes payable, recorded at fair value		102,777
Total liabilities	5,631,673	4,413,234
Commitments and contingencies (Note K)
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively
Common stock, par value $0.001 per share; 200,000,000 and 500,000,000 shares authorized as of September 30, 2020 and 2019, respectively; 5,142,779 and 1,207,993 shares issued and outstanding as of September 30, 2020 and 2019, respectively	5,144	1,208
Additional paid in capital	275,548,737	255,962,922
Accumulated deficit	(269,835,650)	(256,805,589)
Applied DNA Sciences, Inc. stockholders' equity (deficit):	5,718,231	(841,459)
Noncontrolling interest	(8,725)	(7,040)
Total equity (deficit)	5,709,506	(848,499)
Total liabilities and equity (deficit)	11,341,179	3,564,735
Series A Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively
Series B Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively